Royalty Pharma reports Q4 revenue $596M, consensus $691.65M

“Royalty Pharma delivered outstanding results in 2023,” said Pablo Legorreta, Royalty Pharma’s founder and Chief Executive Officer. “We reported another year of strong growth in royalty receipts and deployed substantial capital in value-enhancing transactions, including our strongest year ever for synthetic royalty transactions. Furthermore, a number of positive clinical and regulatory milestones strengthened the outlook for our diversified royalty portfolio. Based on the strong fundamental tailwinds underpinning our business, our strong balance sheet and robust deal pipeline, I am confident we are in an excellent position to fund life sciences innovation and deliver attractive, long-term compounding growth.”